Intersection · Evidence × estimand
Evidence topics tagged estimand
Topics in Evidence carrying the tag estimand. The precise quantity a trial set out to estimate.
65 topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Journal club: indirect comparison between two programmes, defended and attacked
Journal club: indirect comparison between two programmes, defended and attacked Writing it up because I had to work it out twice and would rather nobody else did. Trying to work out what would count as…
|
+122 | 131 | 5.2k | just now |
|
Journal club: LEADER as the historical anchor
Journal club: LEADER as the historical anchor Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of LEADER is wrong? I ask because I have…
|
+103 | 110 | 8.1k | 2h |
|
Second pass at: Reading a trial's population section before its results
Second pass at: Reading a trial's population section before its results Writing it up because I had to work it out twice and would rather nobody else did. Reading STEP 1 ( N Engl J Med , 2021) for the…
|
4 | 9.5k | 10h | |
|
Primary endpoint hierarchies and why order matters — one year on
On the subject in the title: Primary endpoint hierarchies and why order matters — one year on Working notes rather than a conclusion. A follow-up question about Primary endpoint hierarchies that I did not…
|
+56 | 61 | 37k | 11h |
|
Journal club: STEP 8 and the fairness of the comparator dose — a second dataset
Posting this under the heading it deserves: Journal club: STEP 8 and the fairness of the comparator dose — a second dataset Everything below is what sits behind that. Posting a small dataset on STEP 8. It is…
|
+18 | 22 | 656 | 13h |
|
Journal club: semaglutide in MASH, and surrogate endpoints
Posting this under the heading it deserves: Journal club: semaglutide in MASH, and surrogate endpoints Everything below is what sits behind that. Working notes on semaglutide in MASH rather than a conclusion.…
|
+24 | 28 | 17k | 15h |
|
Journal club: STEP 1 and the treatment-policy estimand — does this still hold?
Asking directly, because I could not find a straight answer: Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Working notes on STEP 1 rather than a conclusion. I would rather…
|
+70 | 76 | 4.8k | 15h |
|
Journal club: the CagriSema phase 2 combination paper
On the subject in the title: Journal club: the CagriSema phase 2 combination paper Working notes rather than a conclusion. CagriSema phase 2 combination paper — I have the observation and I do not trust my…
|
2 | 329 | 21h | |
|
Subgroup analyses: pre-specified versus discovered
Subgroup analyses: pre-specified versus discovered — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on subgroup analyses, and I…
|
2 | 27k | 1d | |
|
[2026 update] Journal club: what we got wrong in an earlier session
Journal club: what we got wrong in an earlier session — setting out what I have, and where I think it stops being reliable. Bringing a claim rather than a paper, because the claim is the thing circulating.…
|
+5 | 9 | 4.2k | 1d |
|
Journal club: SUSTAIN 6 and its retinopathy signal
On the subject in the title: Journal club: SUSTAIN 6 and its retinopathy signal Working notes rather than a conclusion. Reading SUSTAIN 6 ( N Engl J Med , 2016) for the population rather than the effect,…
|
+110 | 122 | 46k | 1d |
|
Journal club: orforglipron phase 2 and the non-peptide question
Journal club: orforglipron phase 2 and the non-peptide question Writing it up because I had to work it out twice and would rather nobody else did. Orforglipron phase 2, and specifically the version of it that…
|
+120 | 132 | 13k | 1d |
|
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field — setting out what I have, and where I think it stops being reliable. Collecting what is known about SURMOUNT-OSA in one place,…
|
+108 | 122 | 52k | 7d |
|
[2026 update] Journal club: FLOW and the renal composite, component by component
Journal club: FLOW and the renal composite, component by component Writing it up because I had to work it out twice and would rather nobody else did. A question about what the numbers mean rather than what…
|
2 | 21k | 9d | |
|
Interim analyses and stopping rules
Interim analyses and stopping rules Writing it up because I had to work it out twice and would rather nobody else did. Asking about interim analyses and stopping rules on behalf of the question I keep seeing…
|
+25 | 29 | 35k | 16d |
|
Journal club: STEP 3 and the intensive behavioural therapy floor
Posting this under the heading it deserves: Journal club: STEP 3 and the intensive behavioural therapy floor Everything below is what sits behind that. Two things I would like separated before anyone answers…
|
+6 | 10 | 13k | 28d |
|
Run-in periods and the population they select
On the subject in the title: Run-in periods and the population they select Working notes rather than a conclusion. An honest uncertainty about run-in periods rather than a disguised assertion. I do not know…
|
+130 | 142 | 7.3k | 1mo |
|
Journal club: SELECT, absolute risk, and how it was reported
Journal club: SELECT, absolute risk, and how it was reported Writing it up because I had to work it out twice and would rather nobody else did. A question about what the numbers mean rather than what they…
|
2 | 52k | 1mo | |
|
Journal club: SELECT, absolute risk, and how it was reported — a second dataset
On the subject in the title: Journal club: SELECT, absolute risk, and how it was reported — a second dataset Working notes rather than a conclusion. Posting a small dataset on SELECT. It is mine, it is…
|
4 | 1.3k | 1mo | |
|
Reading a trial's population section before its results
On the subject in the title: Reading a trial's population section before its results Working notes rather than a conclusion. Reading STEP 2 ( Lancet , 2021) for the population rather than the effect, which I…
|
+91 | 109 | 22k | 2mo |
|
Adjudicated events and why the definition matters
On the subject in the title: Adjudicated events and why the definition matters Working notes rather than a conclusion. A follow-up question about adjudicated events that I did not know to ask the first time.…
|
2 | 4.5k | 2mo | |
|
Revisiting: Primary endpoint hierarchies and why order matters
Posting this under the heading it deserves: Revisiting: Primary endpoint hierarchies and why order matters Everything below is what sits behind that. I was wrong about Primary endpoint hierarchies in a thread…
|
+21 | 25 | 46k | 3mo |
|
Subgroup analyses: pre-specified versus discovered — a second dataset
On the subject in the title: Subgroup analyses: pre-specified versus discovered — a second dataset Working notes rather than a conclusion. Posting a small dataset on Subgroup analyses. It is mine, it is…
|
+71 | 79 | 906 | 3mo |
|
Primary endpoint hierarchies and why order matters
Primary endpoint hierarchies and why order matters Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about primary endpoint hierarchies in a thread last spring and…
|
4 | 308 | 3mo | |
|
[2026 update] Composite endpoints and the component doing the work
On the subject in the title: Composite endpoints and the component doing the work Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SURPASS-4 ( Lancet , 2021) and…
|
+76 | 87 | 994 | 3mo |
|
Follow-up: What a statistical analysis plan adds that the paper does not
What a statistical analysis plan adds that the paper does not I have a specific reason for asking rather than idle curiosity, and the context is below. A follow-up question about statistical analysis plan…
|
2 | 7.2k | 3mo | |
|
Open-label extensions: what survives and what does not
Posting this under the heading it deserves: Open-label extensions: what survives and what does not Everything below is what sits behind that. I have spent a fortnight trying to pin open-label extensions down…
|
4 | 22k | 3mo | |
|
Run-in periods and the population they select — the long version
Run-in periods and the population they select — the long version Writing it up because I had to work it out twice and would rather nobody else did. A narrow question about Run-in periods, deliberately narrow,…
|
2 | 8.9k | 4mo | |
|
Journal club: PIONEER 6 as a safety trial
Posting this under the heading it deserves: Journal club: PIONEER 6 as a safety trial Everything below is what sits behind that. Reading PIONEER 6 ( N Engl J Med , 2019) for the population rather than the…
|
+14 | 18 | 262 | 5mo |
|
[2026 update] Journal club: PIONEER 6 as a safety trial
Journal club: PIONEER 6 as a safety trial Writing it up because I had to work it out twice and would rather nobody else did. Bringing a claim rather than a paper, because the claim is the thing circulating.…
|
+14 | 18 | 55k | 5mo |